Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) PT at $152.00

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given a consensus rating of “Moderate Buy” by the twenty-five brokerages that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $152.00.

Several equities research analysts recently commented on the company. Wedbush reiterated an “outperform” rating and set a $152.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. Citigroup boosted their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Barclays boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a report on Thursday, May 2nd. Finally, Wells Fargo & Company raised shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th.

Insider Buying and Selling

In other news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Eric Benevich sold 19,818 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gary A. Lyons sold 12,500 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the completion of the transaction, the director now directly owns 116,947 shares of the company’s stock, valued at $15,861,521.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,697 shares of company stock valued at $13,377,515. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mather Group LLC. acquired a new position in Neurocrine Biosciences during the 1st quarter valued at about $26,000. RFP Financial Group LLC increased its stake in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after acquiring an additional 149 shares during the period. Headinvest LLC bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $28,000. Lindbrook Capital LLC lifted its position in Neurocrine Biosciences by 85.0% in the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares during the period. Finally, EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the 4th quarter valued at $31,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Trading Up 0.5 %

Shares of NBIX stock opened at $138.23 on Friday. The company has a market cap of $13.91 billion, a PE ratio of 38.08 and a beta of 0.37. The company’s fifty day simple moving average is $137.41 and its 200-day simple moving average is $136.07. Neurocrine Biosciences has a 52 week low of $93.28 and a 52 week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. Equities research analysts expect that Neurocrine Biosciences will post 4.19 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.